Progenity Provides Corporate Updates and Reports Third Quarter 2020 Financial Results
09 nov. 2020 16h05 HE
|
Progenity, Inc.
Reported 84 thousand tests in the third quarter, up 12% compared to the second quarter Achieved a preeclampsia test analytical verification milestone Management will host conference call and webcast...
Progenity Announces Encouraging Preclinical Data Supporting the Potential of the Company’s Oral Drug Delivery System in Targeting the Colon
06 nov. 2020 07h30 HE
|
Progenity, Inc.
SAN DIEGO, Nov. 06, 2020 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing...
Progenity to Report Third Quarter 2020 Financial Results and Provide Corporate Update
03 nov. 2020 08h43 HE
|
Progenity, Inc.
SAN DIEGO, Nov. 03, 2020 (GLOBE NEWSWIRE) -- Progenity, Inc. (NASDAQ: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing...
Progenity Announces Successful Achievement of its Preeclampsia Test Analytical Verification Milestone
29 oct. 2020 07h30 HE
|
Progenity, Inc.
Announces Expansion of its COVID-19 Testing Offering Provides Preliminary Third Quarter 2020 Financial Update SAN DIEGO, Oct. 29, 2020 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a...
Progenity Presents Data from Award-Winning Abstract on Novel Ingestible Lab-in-a-Capsule at American College of Gastroenterology (ACG) 2020 Virtual Annual Meeting
27 oct. 2020 07h30 HE
|
Progenity, Inc.
SAN DIEGO, Oct. 27, 2020 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing...
Progenity to Present Precision Medicine Abstracts at American College of Gastroenterology (ACG) Virtual Annual Meeting in October
09 oct. 2020 07h30 HE
|
Progenity, Inc.
SAN DIEGO, Oct. 09, 2020 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing...
Progenity Supports the Preeclampsia Foundation Call to Action to Accelerate Development and Adoption of Biomarker Tests for Preeclampsia
01 oct. 2020 07h30 HE
|
Progenity, Inc.
SAN DIEGO, Oct. 01, 2020 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing...
Progenity Announces Addition to Russell 2000® Index
18 sept. 2020 07h30 HE
|
Progenity, Inc.
SAN DIEGO, Sept. 18, 2020 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing...
Progenity to Participate in Two Upcoming Investor Conferences
02 sept. 2020 07h30 HE
|
Progenity, Inc.
SAN DIEGO, Sept. 02, 2020 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing...
Progenity Commends New Recommendations from ACOG and SMFM Supporting Non-Invasive Prenatal Testing (NIPT) for All Pregnancies
21 août 2020 07h30 HE
|
Progenity, Inc.
SAN DIEGO, Aug. 21, 2020 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing...